Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mdw025
复制
发表时间：
2016-09-01
影响因子：
50.5
通讯作者：
Buske, C.
中科院分区：
文献类型：
--
作者：
Hoelzer, D.;Bassan, R.;Buske, C.
在欧洲，急性淋巴细胞白血病（ALL）和淋巴母细胞淋巴瘤的估计总发病率为每年1.28/100000人，具有显著的年龄相关变化（45-54岁时为0.53，55-74岁为1.0，75-99岁为1.45），伯基特白血病/淋巴瘤在相同年龄组中的比例在0.17和0.33之间[1]。这些数字使ALL成为成人罕见疾病，因此非常需要在合格的中心进行评估和护理。与儿童ALL相反，成人ALL的易感风险因素尚不清楚[2]。如大量登记数据所示，治疗进展是不可否认的。在欧洲，5年总生存率（OS）从1997-1999年的29.8%提高到2006-2008年的41.1%（P< 0.0001），仍然是年龄的函数。与参考组（年龄15-54岁：OS> 50%）相比，55-64岁年龄组的OS < 30%（风险比2.05），≥ 65岁年龄组的OS < 20%（风险比2.71和3.75）[3]。
The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related variations (0.53 at 45–54 years,∼ 1.0 at 55–74 years and 1.45 at 75–99 years) and that of Burkitt leukaemia/lymphoma is between 0.17 and 0.33 in the same age groups [1]. These figures qualify ALL as a rare disease in adults, making assessment and care at qualified centres highly desirable. Predisposing risk factors for adult ALL are not known, contrary to childhood ALL [2]. Therapeutic progress is undeniable as shown by large registry data. In Europe, 5-year overall survival (OS) improved from 29.8% in the years 1997–1999 to 41.1% in 2006–2008 (P< 0.0001), still as a function of age. Compared with the reference group (age 15–54 years: OS> 50%), OS was< 30% in the 55–64 years age group (hazard ratio 2.05) and< 20% in the≥ 65 years age group (hazard ratios 2.71 and 3.75)[3].